Over SEK 90 million awarded to OnkPat researchers by the Swedish Cancer Society

Among the recipients is OnkPat researcher Fredrik Strand, who has been awarded a total of SEK 26.5 million for two breast cancer research projects. One of these, receiving SEK 22 million, focuses on AI-driven screening, risk identification, and multimodal surveillance, and is part of the Swedish Cancer Society’s special initiative for early cancer detection

Project grants to OnkPat researchers from the Swedish Cancer Society in 2025

Svetlana Bajalica Lagercrantz – SEK 3,000,000 for the project “The Swedish constitutional TP53 cohort (SWEP53): genotype-phenotype prediction and improved ‘previvorship’ and survival” (2026–2028)

Jonas Bergh – SEK 6,750,000 for “Translational breast cancer studies with a focus on prognostics, treatment prediction and tailored therapy strategies” (2026–2028)

Felix Haglund de Flon – SEK 3,000,000 for “TAXOSARC – A data-driven redefinition of sarcoma taxonomy” (2026–2028)

Lotta Hansson – SEK 3,000,000 for “Chronic lymphocytic leukemia (CLL) – real-world effects of precision medicine and clinical/immunological studies in CLL patients post virus infection/vaccination” (2026–2028)

Rolf Kiessling – SEK 3,500,000 for “Development of cell therapy methods and biomarkers for immune therapy” (2026–2027)

Ola Larsson – SEK 4,500,000 for “Evaluating novel mechanisms that control mRNA translation as targets in hard-to-treat cancers” (2026–2028)

Linda Lindström – SEK 4,500,000 for “Identification of tumour features influencing LATE risk of metastasis and long-term benefit from endocrine treatment in ER+ breast cancer” (2026–2028)

Alexios Matikas – SEK 3,000,000 for “Integrated multi-omics for prediction of response to antibody-drug conjugate” (2026–2028)

Pär Nordlund – SEK 6,000,000 for “Pathways-CETSA derived biomarkers for efficacy and resistance to improve cancer therapies” (2026–2028)

Rolf Ohlsson – SEK 2,000,000 for “A new mechanism for bypassing MYC negative feedback loops restricting cancer cell expansion: underlying principles and new targets for intervention” (2026–2027)

Lukas Orre – SEK 3,000,000 for “Investigation of immune evasion mechanisms in STK11-inactivated NSCLC” (2026–2028)

Georgios Rassidakis – SEK 3,000,000 for “Targeting antitumor immune response mechanisms in lymphomas: implications for precision molecular therapeutics and immunotherapy” (2026–2028)

Susanne Schlisio – SEK 6,000,000 for “Cell stage dynamics and plasticity in malignant neuroendocrine tumours during tumour formation and therapy resistance” (2026–2028)

Fredrik Strand – SEK 4,500,000 for “Advancing multimodal AI models for precision breast cancer diagnosis and treatment guidance” (2026–2028)

Thuy Tran – SEK 3,000,000 for “Translational studies of precision theranostics with antibody-based radiopharmaceuticals for metastatic solid cancers” (2026–2028)

Anders Ullén – SEK 4,500,000 for “Translational studies of advanced and metastatic bladder cancer – from identification of new biomarkers and treatment strategies to clinical trials” (2026–2028)

Stina Wickström – SEK 3,000,000 for “Development and implementation of adoptive cell therapy for gynaecological cancers” (2026–2028)

Pia Österlund – SEK 1,600,000 for “Clinical factors, mutational landscape, and tumour microenvironment of metastatic colorectal cancer as prognostic and treatment-predictive biomarkers” (2026–2027)

Grants for early cancer detection research

Fredrik Strand – SEK 22,000,000 for “Early Detection of Breast Cancer through AI-guided Screening, Risk Identification and Multi-Modal Surveillance” (2026–2029)

Planning grants for multicentre studies

Hildur Helgadottir – SEK 750,000 for work with the Swedish Melanoma Study Group (SMSG) (2026–2028)